Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Faron Pharmaceuticals

Faron Pharmaceuticals
2007 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
FARN STOCK SYMBOL
$1.67 SHARE PRICE (As of Friday Closing)
Description

Faron Pharmaceuticals Oy is a Finnish drug research and discovery company. The company is focused on developing novel therapeutics for medical conditions with unmet needs such as acute organ traumas, cancer immunotherapy, and vascular damage. Its pipeline of drugs is comprised of its lead product Traumakine (FP-1201-lyo) and Clevagen (FP-1304). Traumakine addresses Acute Respiratory Distress Syndrome and is currently in its phase-3 of development. Clevagen is an immunotherapy tumor targeting candidate that is in pre-clinical stage development. The Company's main sources of revenue have been upfront payments (one-off license payments), revenues from product sales and milestone payments in accordance with the license agreements.

Website
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
LON
Primary Office
  • Joukahaisenkatu 6
  • Intelligate
  • 20520 Turku
  • Finland

+358 02 0000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Faron Pharmaceuticals’s full profile, request a free trial.

Faron Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.63 - $2.12 $65.8M $1.76 -$0.42 106K 39.4M

Faron Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 49,455 11,387 306,894 78,194
Revenue 0 22 0 1,053
EBITDA (13,939) (23,440) (23,580) (11,018)
Net Income (14,188) (23,703) (23,752) (11,214)
Total Assets 5,802 9,154 17,860 16,561
Total Debt 2,687 2,439 2,910 2,289
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Faron Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Faron Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Faron Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
Markku Jalkanen Ph.D Chief Executive Officer & Board Member
Yrjö Wichmann Chief Financial Officer
Mikael Maksimow Ph.D Co-Founder & Vice President of Operations

Faron Pharmaceuticals Board Members (5)

Name Representing Role Since Contact
Info
00000 000000000 00 Self Chairman & Board Member 000 0000
0000 000000 Self Board Member 000 0000
00000000 0000000000 Self Board Member 000 0000
000000 00000000 00.0 Faron Pharmaceuticals Chief Executive Officer & Board Member 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »